Linzess, Constella (linaclotide) is a protein pharmaceutical. Linaclotide was first approved as Linzess on 2012-08-30. It is used to treat constipation and irritable bowel syndrome in the USA. It has been approved in Europe to treat irritable bowel syndrome. The pharmaceutical is active against heat-stable enterotoxin receptor. Linzess's patents are valid until 2033-08-16 (FDA).
|Indication||constipation, irritable bowel syndrome|
|Drug Class||Peptides: gastrointestinal functions; normalising agent|